Eli Lilly's eczema drug EBGLYSS has demonstrated sustained, multi-year effectiveness, highlighting the lucrative potential of targeted biologic therapies. This clinical milestone validates the broader dermatology market, creating opportunities for biopharmaceutical companies developing innovative skin treatments.
Published on March 28
Four years of proven skin clearance from a single biologic therapy signals a turning point for the entire dermatology sector. When one treatment proves long-term results, investors start paying serious attention to every company in the space.
Chronic skin conditions require ongoing care, which means successful therapies don't just sell once. Companies with durable, long-lasting treatments can build highly predictable revenue streams that keep delivering year after year.
From rare genetic skin diseases to immune-mediated conditions, a wave of next-generation biologics is moving through clinical development right now. Experts are watching this space closely, and the timing could be significant for early movers.
A recent clinical breakthrough for Eli Lilly's eczema drug EBGLYSS, showing four years of sustained skin clearance, has shone a spotlight on the enormous commercial potential of targeted biologic therapies. This group captures that momentum, bringing together pharmaceutical leaders and agile biotech firms that are developing the next generation of treatments for chronic skin conditions, all without relying on traditional steroids.
These companies operate across the full spectrum of dermatology, from discovery and clinical trials through to commercialization. They focus on chronic conditions like eczema, psoriasis, and rare genetic skin diseases, areas where patients need long-term, reliable care. Because these treatments are ongoing rather than one-off, successful therapies can generate predictable, recurring revenue, which many investors find attractive.
Each stock in this group was handpicked by professional analysts based on its role in advancing dermatological innovation. The selection spans established pharmaceutical companies with proven commercial products and smaller biotech firms building exciting pipelines. Together, they offer a broad view of a therapeutic category that is gaining significant investor attention thanks to growing patient demand and strong clinical momentum.
This basket's total market capitalisation is 836,060.50979 and is heavily anchored by a single very large-cap constituent, with much smaller firms comprising the remainder. Consequently, the basket tends to reflect large-cap dynamics rather than small-cap biotech volatility.
LLY: $829.78B
ARQT: $2.63B
CLDX: $2.02B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Read Full Insight
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+3
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Current Price
$1,142.85
Eli Lilly's eczema drug EBGLYSS has shown sustained multi-year effectiveness, highlighting the lucrative potential of targeted biologic therapies in d...
Eli Lilly's eczema drug EBGLYSS has shown sustained multi-year effectiveness, highlighting the lucrative potential of targeted biologic therapies in dermatology.
ARCUTIS BIOTHERAPEUTICS INC
ARQT
Current Price
$25.16
Arcutis Biotherapeutics is a commercial-stage medical dermatology company developing treatments for immune-mediated skin diseases like atopic dermatit...
Arcutis Biotherapeutics is a commercial-stage medical dermatology company developing treatments for immune-mediated skin diseases like atopic dermatitis and plaque psoriasis.
BIOCRYST PHARMACEUTICALS INC
BCRX
Current Price
$8.17
BioCryst Pharmaceuticals is expanding its rare disease focus by developing early-stage targeted therapies for severe dermatological conditions such as...
BioCryst Pharmaceuticals is expanding its rare disease focus by developing early-stage targeted therapies for severe dermatological conditions such as atopic dermatitis.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+197.36%
On average, analysts expect assets in this group to grow 197.36% over the next year.
10 of 12 assets in this group are rated Buy by professional analysts.
